KCS Wealth Advisory trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,936 shares of the company’s stock after selling 102 shares during the period. KCS Wealth Advisory’s holdings in Johnson & Johnson were worth $282,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in JNJ. Phocas Financial Corp. grew its stake in Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after buying an additional 125,161,066 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Johnson & Johnson by 5,447.1% during the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock worth $2,357,266,000 after buying an additional 16,619,550 shares in the last quarter. Johanson Financial Advisors Inc. grew its stake in Johnson & Johnson by 14,438.5% during the fourth quarter. Johanson Financial Advisors Inc. now owns 2,470,520 shares of the company’s stock worth $16,935,000 after buying an additional 2,453,527 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after buying an additional 2,204,757 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after purchasing an additional 1,627,370 shares in the last quarter. Hedge funds and other institutional investors own 67.28% of the company’s stock.
JNJ opened at $147.01 on Thursday. The company’s 50 day moving average is $143.07 and its 200-day moving average is $134.77. Johnson & Johnson has a 1-year low of $125.00 and a 1-year high of $147.84. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The company has a market cap of $385.62 billion, a P/E ratio of 17.97, a PEG ratio of 2.36 and a beta of 0.71.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.58%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
In related news, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now directly owns 51,736 shares in the company, valued at approximately $7,298,397.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Hubert Joly bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is owned by company insiders.
JNJ has been the topic of a number of research analyst reports. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Credit Suisse Group restated a “buy” rating and issued a $163.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research note on Wednesday, December 18th. Morgan Stanley upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $145.00 to $170.00 in a research note on Tuesday, December 17th. Finally, Wells Fargo & Co raised their price target on shares of Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $159.33.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Cost of Goods Sold (COGS)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.